EGFR and nonpapillary renal cell carcinoma: The unique ccRCC gene expression signatures revealed drug candidates for repositioning, with a strong tendency to target small-molecule-based drugs, with erlotinib (epidermal growth factor receptor (EGFR) inhibitor) being one of the top eight drug candidates.